Evidence map›Paper›PMID 29101615›Full record

Trial reportInternational journal of clinical pharmacy2017

Trough level from twice daily to once daily tacrolimus in early conversion kidney transplant recipients: a prospective study.

Sayamon Sukkha, Busba Chindavijak, Preecha Montakantikul, Atiporn Ingsathit, Wichit Nosoongnoen, Vasant Sumethkul

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in International journal of clinical pharmacy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Observational
  2. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Sayamon SukkhaDivision of Clinical Pharmacy, Department of Pharmacy, Faculty of Pharmacy, Mahidol University, 447 Sri Ayutthaya Road, Rajathevi, Bangkok, 10400, Thailand.
Busba ChindavijakDivision of Clinical Pharmacy, Department of Pharmacy, Faculty of Pharmacy, Mahidol University, 447 Sri Ayutthaya Road, Rajathevi, Bangkok, 10400, Thailand.
Preecha MontakantikulDivision of Clinical Pharmacy, Department of Pharmacy, Faculty of Pharmacy, Mahidol University, 447 Sri Ayutthaya Road, Rajathevi, Bangkok, 10400, Thailand.
Atiporn IngsathitDepartment of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, 270 Rama VI Road, Rajathevi, Bangkok, 10400, Thailand.
Wichit NosoongnoenDivision of Clinical Pharmacy, Department of Pharmacy, Faculty of Pharmacy, Mahidol University, 447 Sri Ayutthaya Road, Rajathevi, Bangkok, 10400, Thailand. wichit.nos@mahidol.ac.th.
Vasant SumethkulDepartment of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, 270 Rama VI Road, Rajathevi, Bangkok, 10400, Thailand.
Mahidol University · THRamathibodi Hospital · TH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background Early conversion from twice-daily tacrolimus (TAC-BID) to once-daily tacrolimus (TAC-OD) provides a greater benefit of reducing under-exposure of TAC-OD during the first period after transplantation. Information regarding the conversion dose among Asian kidney transplant recipients is still limited. Objective This study aimed to compare the trough levels (C

Indexed as

Drug Administration ScheduleFemaleHospitals, UniversityHumansImmunosuppressive AgentsKidney TransplantationMaleProspective StudiesTacrolimusImmunosuppressive AgentsTacrolimusEarly conversionFormulationKidney transplantTacrolimusTrough level

Identifiers

PMID29101615
OpenAlexW2767174288

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.